Published • loading... • Updated
Bayer to Buy Perfuse Therapeutics in up to $2.45 Billion Deal
Bayer will pay $300 million upfront and up to $2.15 billion more for PER-001, which is in mid-stage testing for glaucoma and diabetic retinopathy.
- On Wednesday, Bayer agreed to acquire Perfuse Therapeutics in a deal worth up to $2.45 billion, marking the German pharmaceutical giant's first major drug acquisition in years. The transaction includes a $300 million upfront payment with additional milestone payments tied to regulatory and commercial success.
- Following the patent expiry of Eylea, Bayer's best-selling eye drug, the company faces declining sales due to biosimilar competition and alternative medicines. This acquisition aims to bolster the ophthalmology pipeline and restore growth in a core therapeutic area.
- Bayer will acquire full rights to PER-001, a small molecule therapy currently in Phase 2 clinical development targeting glaucoma and diabetic retinopathy. The drug blocks a protein that constricts blood vessels and contributes to ocular damage in these conditions.
- Juergen Eckhardt, head of business development and licensing at Bayer's pharmaceuticals division, stated the acquisition complements the company's "expertise in ophthalmology" and reinforces commitment to "developing urgently needed therapies for patients." CEO Bill Anderson, a former Roche executive, has prioritized such strategic acquisitions since 2023.
- Completion requires antitrust regulatory clearances and approval from Perfuse stockholders. If all performance milestones are met, the acquisition would be Bayer's largest since its 2020 takeover of Asklepios BioPharmaceuticals.
Insights by Ground AI
16 Articles
16 Articles
Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus
Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy. The post Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeli…
Coverage Details
Total News Sources16
Leaning Left1Leaning Right1Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 17%
C 67%
R 16%
Factuality
To view factuality data please Upgrade to Premium
